Geode Capital Management
RPRX icon

Geode Capital Management’s Royalty Pharma RPRX Stock Holding History

Geode Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$451M Buy
8,058,048
+188,416
+2% +$9.81M 0.02% 497
2026
Q1 		$377M Buy
7,869,632
+149,789
+2% +$6.56M 0.02% 521
2025
Q4 		$297M Buy
7,719,843
+102,430
+1% +$3.91M 0.02% 584
2025
Q3 		$268M Sell
7,617,413
-559,091
-7% -$20.2M 0.02% 609
2025
Q2 		$299M Buy
8,176,504
+177,036
+2% +$5.87M 0.02% 539
2025
Q1 		$253M Buy
7,999,468
+686,917
+9% +$21.8M 0.02% 567
2024
Q4 		$187M Buy
7,312,551
+46,765
+0.6% +$1.24M 0.01% 658
2024
Q3 		$206M Buy
7,265,786
+417,490
+6% +$11.6M 0.02% 623
2024
Q2 		$180M Buy
6,848,296
+300,242
+5% +$8.32M 0.02% 633
2024
Q1 		$199M Buy
6,548,054
+180,443
+3% +$5.32M 0.02% 594
2023
Q4 		$179M Buy
6,367,611
+266,057
+4% +$7.31M 0.02% 586
2023
Q3 		$166M Sell
6,101,554
-44,310
-0.7% -$1.32M 0.02% 578
2023
Q2 		$189M Buy
6,145,864
+153,738
+3% +$5.21M 0.02% 549
2023
Q1 		$216M Buy
5,992,126
+165,332
+3% +$6.13M 0.03% 497
2022
Q4 		$230M Buy
5,826,794
+555,060
+11% +$23.2M 0.03% 470
2022
Q3 		$212M Buy
5,271,734
+220,646
+4% +$9.42M 0.03% 468
2022
Q2 		$212M Buy
5,051,088
+41,439
+0.8% +$1.7M 0.03% 481
2022
Q1 		$195M Sell
5,009,649
-294,473
-6% -$11.6M 0.02% 543
2021
Q4 		$211M Buy
5,304,122
+1,136,073
+27% +$44.1M 0.03% 536
2021
Q3 		$151M Buy
4,168,049
+2,183,363
+110% +$84.8M 0.02% 608
2021
Q2 		$81.2M Buy
1,984,686
+54,236
+3% +$2.31M 0.01% 932
2021
Q1 		$84.1M Buy
1,930,450
+677,943
+54% +$32.1M 0.01% 873
2020
Q4 		$62.6M Buy
1,252,507
+167,664
+15% +$7.11M 0.01% 957
2020
Q3 		$45.6M Buy
1,084,843
+254,569
+31% +$10.9M 0.01% 969
2020
Q2 		$40.3M Buy
+830,274
New +$41.1M 0.01% 1010

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $2.93B AUM 37.21% 1-Year Est. Return

Geode Capital Management's RPRX Position: Q2 2026 in Review

Geode Capital Management increased its Royalty Pharma (RPRX) stake by 2.4% in Q2 2026, buying an estimated $9.81M and bringing the position to 8,058,048 shares worth $451M. The position accounts for 0.02% of the portfolio, ranked #497.

Geode Capital Management first reported a position in RPRX in Q2 2020 and has held it in 25 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Geode Capital Management held 8,058,048 shares of Royalty Pharma worth $451M as of Q2 2026.
  • Geode Capital Management bought 188,416 Royalty Pharma shares in Q2 2026, an estimated $9.81M.
  • Royalty Pharma made up 0.02% of Geode Capital Management's portfolio in Q2 2026, its #497 holding.
  • Geode Capital Management first reported a position in Royalty Pharma in Q2 2020 and has held it in 25 quarters since.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.